Biological implications of circulating CD34+ cells in myelodysplastic syndromes

Journal of B.U.ON.

Volumn 15, Issue 4, 2010, Pages 753-757

  Marisavljevic, Dragomir ^a   Kraguljac Kurtovic, N ^b  

^a University Medical Center Bezanijska Kosa   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Biology; CD34+ cells; Myelodysplastic syndromes; Peripheral blood; Prognosis

Indexed keywords

CD34 ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW; CELL COUNT; CELL GROWTH; CIRCULATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COLONY FORMING UNIT GM; CONTROL GROUP; CORRELATION ANALYSIS; CYTOGENETICS; EMERGENCY TREATMENT; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BONE MARROW; CASE-CONTROL STUDIES; CHROMOSOME ABERRATIONS; COLONY-FORMING UNITS ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID CELLS; PROGNOSIS; SURVIVAL RATE;

EID: 78651402335     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ogata K, Yoshida Y. Clinical implications of blast immunophenotypes in myelodysplastic syndromes. Leuk Lymphoma 2005; 46: 1269-1274.
2. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002; 100: 3553-3560.
3. Sawada K, Sato N, Notoya A et al. Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ cells. Blood 1995; 85: 194-202.
4. Sawada K, Sato N, Notoya A et al. Proliferation and differentiation of myelodysplastic CD34+ cells in serum-free medium: II. Response to combined colony-stimulating factors. Eur J Haematol 1995; 54: 85-94.
5. Tohyama K, Ueda T, Yoshida Y, Nakamura T. Altered responses of purified blast cells from the myelodysplastic syndromes to colony-stimulating factors in vitro: comparison with normal blast cells. Exp Hematol 1994; 22: 539-545. (Pubitemid 24300486)
6. Sawada K, Ieko M, Notoya A et al. Role of cytokines in leukemic type growth of myelodysplastic CD34+cells. Blood 1996; 88: 319-327.
7. Claessens YE, Bouscary D, Dupont JM et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002; 99: 1594-1601.
8. Guyotat D, Campos L, Thomas X et al. Myelodysplastic syndromes: a study of surface- markers and in vitro growth patterns. Am J Hematol 1990; 34: 26-31.
9. Soligo DA, Oriani A, Annaloro C et al. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. Am J Hematol 1994; 46: 9-17.
10. Arroyo JL, Fernandez ME, Hernandez JM et al. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. Hematol J 2004; 5: 227-233.
11. Sullivan SA, Marsden KA, Lowenthal RM, Jupe DM, Jones ME. Circulating CD34+ cells: an adverse prognostic factor in the myelodysplastic syndromes. Am J Hematol 1992; 39: 96-101.
12. Bennett J, Catovsky D, Flandrin G, Galton D, Gralnick H, Sultan C. The French-American-British (FAB) cooperative group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-99.
13. Reizenstein P, Ost A. Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leuk Res 1992; 16: 3-11.
14. N. Kraguljac, D. Marisavljević, G. Janković et al. Characterization of CD13 and CD33 surface antigen-negative acute myeloid leukemia. Am J Clin Pathol 2000; 114: 29-34.
15. Roche G, Scvhmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia 1996; 10: 877-895.
16. Novak A, Kruskić M, Ludoški M et al. Rapid method for obtaining high quality chromosome banding in the study of hemopoietic neoplasia. Cancer Genet Cytogenet 1994; 74: 109-114.
17. ISCN. Mitelman F (Ed): An International System for Human Genetic Nomenclature. Karger, Basel, 1995.
18. Iscove N, Sieber F, Winterhalter K. Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement of erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol 1974; 83: 309-320.
19. Messner H, Jamal N, Izaguirre C. The Growth of Large Megakaryocyte Colonies From Human Bone Marrow. J Cell Physiol 1982; (Suppl 1): 45-51.
20. Raymakers R, Preijers F, Boezeman J, Rutten E, De Witte T. Prognostic implications of bone marrow culturing in myelodysplastic syndrome: a retrospective analysis. Leuk Lymphoma 1993; 14: 111-120.
21. Fuchigami K, Mori H, Matsuo T et al. Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry. Leuk Res 2000; 24: 163-174.
22. List A, Vardiman J, Issa JP, DeWitte T. Myelodysplastic syndromes. Am Soc Hematol Educ Program. Hematology 2004: 297-317.
23. Ogata K, Satoh C, Tachibana M et al. Identification and hematopoietic potential of CD45- clonal cells with very immature phenotype (CD45-CD34-CD38-Lin-) in patients with myelodysplastic syndromes. Stem Cells 2005; 23: 619-630. (Pubitemid 40647258)
24. Meletis J, Terpos E. Transplantation strategies for the management of patients with myelodysplastic syndromes. J BUON 2009; 14: 551-564.